Safety study of a test system for Loargys-treated patients
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study evaluates whether a new test system is safe to use in patients who are already taking Loargys (a medicine for a rare condition called ARG1-D, which affects how the body processes a protein building block called arginine). The study simply observes how the test system works in people already on this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must currently be taking Loargys medicine for ARG1-D
- You must be willing to sign an informed consent form (a document stating you understand the study and agree to participate)
- No other medical conditions will disqualify you from this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether replacing the body’s arginine (an amino acid) can improve outcomes for children and young adults hospitalized with COVID-19. It may help the immune response, but you must meet several safety criteria to join.
This study tests a new medicine called BAY 3401016 to see if it can help adults with Alport syndrome, a genetic condition that affects the kidneys. The drug is given as an infusion or injection and the study will check how well it works and if it is safe.
This trial studies whether taking arginine changes how well people do soon after an islet transplant. It may help improve early outcomes and guide care for people who are getting ready for this treatment.
This trial tests a new drug called ARGX-124 in healthy people to see if it is safe. It is a first step before testing it in patients with certain conditions.
This study follows people who have (or might have) NAGS deficiency and who are taking Carbaglu to treat it. The goal is to better track safety and health outcomes over time.
This is an early-stage study testing a new investigational medicine called ALN-4915 in healthy volunteers. Researchers want to learn if it is safe and how the body processes it.
Hear when a new ARG1 Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.